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low-up of 21 adult patients with acute leukemia treated with pe-
ripheral blood HPCT following RIC after being deemed
inadequate for fully myeloablative conditioning. A matched com-
parison arm of 42 consecutive patients transplanted after full my-
eloablative (FMA) conditioning is also reported. Methods: Be-
tween 1999–2004, 21 patients were treated with Fludarabine-based
conditioning prior to infusion of hematopoietic stem cells. Patients
were followed for toxicities and responses. IRB approval was ob-
tained prior to data collection. Kaplan-Meier estimates of survival
were performed. Patient disease characteristics were analyzed us-
ing T-tests to determine any factors that may be associated with
outcome and relapse. Signiﬁcant factors on univariate analysis were
placed into a Cox regression model for multivariable analysis.
Results: Patient characteristics: 76% of patients had AML and
24% had ALL. 14% of patients had relapsed or refractory disease
at transplant. A greater proportion of patients undergoing RIC,
had poor-risk cytogenetics. Median age was 56 yrs. 81% of patients
experienced clinically signiﬁcant acute or chronic GVHD. Overall
post-transplant survival was 29%. Twenty-nine percent (6/21) pa-
tients suffered relapse at a median of 4 months post-transplant.
Cox proportional hazards models for overall post-transplant sur-
vival and logistic regression models for relapse and overall survival
(N  63), showed that the only signiﬁcant predictor for OS and
relapse was cytogenetic risk group (P  .000). Of note, none of the
5 ALL patients transplanted after RIC have relapsed with a median
follow-up of 2.2 years (0.1–3.9 years); among 16 AML pts., 5 have
relapsed with median follow-up of 0.4 years (.1–2.2 years). These
results compare favorably to our cohort of pts. transplanted after
full myeloablative conditioning. Conclusion: The role of RIC
transplants for the treatment of high risk acute leukemia in older





N  21 (%)
Comparison
arm (FMA)
N  42 (%)
ALL 5 (24%) 10 (24%)
AML 16 (76%) 32 (76%)
Median age 56 (45–68) 52 (41–62)
Male 14 (67%) 20 (48%)
Disease status at
transplant:
CR1 13 (62%) 30 (71%)
CR2–3 4 (19%) 7 (17%)
Relapsed-
Refractory
3 (14%) 5 (12%)
Donor: Related 12 (57%) 34 (81%)
Unrelated 9 (43%) 8 (19%)
Cytogenetic risk: *
Favorable 1 (5%) 4 (10%)
Intermediate 6 (28%) 19 (45%)
Poor 14 (76%) 18 (43%)
*1 Pt, cytogenetics were unknown
199
INVESTIGATING THE ROLE OF DENDRITIC CELLS IN EXTRACORPO-
REAL PHOTOPHERESIS USING AN IN VITRO MODEL
Holtick, U.1, Marshall, S.R.1, Wang, X.N.1, Hilkens, C.M.U.2,
Dickinson, A.M.1 1. Haematological Sciences; 2. Rheumatology, The
Medical School, University of Newcastle upon Tyne, United Kingdom.
Graft-versus-host disease (GvHD) is the major complication
after allogeneic transplantation and contributes signiﬁcantly to
transplant related mortality and morbidity. Especially steroid
refractory or steroid depending GvHD is linked to poor survival
or life quality. Conventional immunosuppression has very lim-
ited success in these conditions and increases susceptibility for
infection and relapse. Extracorporeal Photopheresis (ECP) is a
promising therapy for acute and chronic GvHD not responding
to conventional immunosuppressive therapy. ECP treatment
seems not to result in a pan-immunosuppression but has quite
selective effects on the pathogenic process in GvHD. The
mechanisms of action of ECP in GvHD known so far include
lymphocyte senescence or apoptosis and cytokine modulation.
Some groups report that antigen presenting cells like dendritic
cells (Dc) might be important for ECP mechanisms. We have
developed an in vitro model of ECP (in vitro PUVA) to inves-
tigate ECP effects on dendritic cells. Initial experiments have
shown the maturation of monocyte derived Dcs treated with in
vitro PUVA (upregulation of CD83, CD86, HLA-DR as well as
reduced endocytosis capacity), but also the induction of apopto-
sis. The stimulatory capacity of in vitro PUVA treated Dcs was
strongly inhibited in autologous and allogeneic MLR. However,
treatment of antigen-primed Dcs resulted in less inhibition,
suggesting factors that might preserve Dc stimulatory capaci-
ties. Immature Dcs, retrieved after coculture with in vitro
PUVA treated lymphocytes, show inhibited stimulatory capacity
on autologous and allogeneic T cells. Currently, we are inves-
tigating the changes in phenotype and cytokine pattern which
could transfer anergy or promote tolerance induction. In par-
allel, we are analyzing effects on monocyte-derived dendritic
cells from patients undergoing ECP treatment for chronic
GvHD. Dcs rendered tolerogenic could play a major role in
ECP mechanisms.
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HUMAN T LYMPHOCYTE ACTIVATION KINETICS FOR IDENTIFYING AND
TARGETING ALLOREACTIVE T CELLS
Bajwa, R.P.S., McCarthy, P.L., Wallace, P.K., Wallace, S., Wu, Y.,
Battiwalla, M. Roswell Park Cancer Institute, Buffalo, NY.
Selective depletion of alloreactive T cells from a stem cell graft
has the potential of reducing graft-versus-host disease (GvHD) while
preserving graft-versus-leukemia (GvL) and third party responses. For
this purpose several techniques generate and deplete alloreactive cells,
which are donor-derived T cells activated by recipient tissue. The
kinetics of T cell activation in donor-recipient co-culture systems is
critical in optimizing the timing of depletion of alloreactive T cells.
We present the T cell activation kinetics in our preclinical system.
Peripheral blood mononuclear cells (PBMCs) were derived form
several pairs of unrelated healthy human volunteers. 2500 cGy irra-
diated cells (stimulators) were co-cultured with PBMCs (responders)
in a 1:1 ratio and a concentration of 5  106/ml in serum free
medium. Stimulator cells were labeled with PKH67 and the co-
cultures were, analyzed for CD3, CD4, and CD25, expression by ﬂow
cytometry on days 0 through 7, using Topro-3 to exclude dead cells.
Our results show that CD3, CD4, CD25 cells (alloreactive CD8
cells) increased from 1 % on day 0, to 6.5 percent by day 5; the
addition of IL2 ampliﬁed the increment to nearly 10% by day 5.
CD3, CD4, CD25dim or total cells (CD4 activated T cells)
did not appreciably increase over time and ranged between 2 to
5%; the addition of IL2 did not have any effect. The CD3,
CD4, CD25bright cells (T regulatory cells) increased from
1% at baseline to 5% by day 5 and these were unaffected by
the addition of IL2. The proportion of non-activated T lym-
phocytes, decreased with time of co-culture progression. Our
results show that T lymphocyte activation, deﬁned by CD25
expression, progressively increases through the ﬁrst week of
co-culture. This important observation will help in establishing
the timing of allograft manipulation, for the selective depletion
of alloreactive T cells in clinical hematopoietic stem cell trans-
plantation.
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SIROLIMUS/MYCOPHENOLATE MOFETIL (MMF) AS TREATMENT FOR
GRAFT-VERSUS-HOST-DISEASE IN TWO CHILDREN WITH SEVERE RE-
NAL AND CALCINEURIN-INHIBITOR-ASSOCIATED CENTRAL NERVOUS
SYSTEM (CNS) TOXICITY
Ehlert, K., Groll, A.H., Vormoor, J. University Hospital, Department of
Pediatric Hematology and Oncology, Muenster, Germany.
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Introduction: Ciclosporin A (CsA) is considered to be a major
component in the prophylaxis and treatment of acute and chronic
graft-versus-host-disease (GvHD) after allogeneic hematopoietic
stem cell transplantation (HSCT). However, impairment of renal
function and CNS toxicity may complicate or even inhibit the use
of calcineurin-inhibitors (CNI). Here, we report the use of siroli-
mus/MMF in two children with acute/chronic GvHD and signif-
icant CNI-associated toxicities. Case Reports: Two patients, a
14-year-old boy and a 4-year-old girl, were transplanted for ALL
and AML, respectively. They received bone marrow from their
HLA-identical siblings and GvHD-prophylaxis with MTX and
CsA. Patient 1, the boy, stayed on CsA until day 27, when he
complained of dizziness and disorientation. The cranial MRI ﬁnd-
ings were consistent with CsA-induced neurotoxicity. He was set
on tacrolimus until day 95, when he presented with cerebral
seizures and somnolence. In the absence of acute GvHD and the
presumption of tacrolimus-induced neurotoxicity, the drug was
discontinued. One week later, the presence of GvHD of skin and
gut could be conﬁrmed by biopsy. During his previous anti-leuke-
mic therapy, the patient had suffered from severe side effects of
high-dosed steroids. So, in an attempt to minimize the use of
steroids, he was set on sirolimus/MMF with a short course of
prednisone. He rapidly responded to this regimen. Steroids were
discontinued after a few days. The boy stayed on sirolimus/MMF
for four months without evidence of recurrent GvHD. Patient 2
was switched early to tacrolimus because of a status of stupor
and suspected CsA-neurotoxicity. She developed stage 4 gut
GvHD on day 45, responsive to a highly immunosuppressive
therapy including inﬂiximab. Eleven months post-transplant,
while on tacrolimus, she had increasing renal insufﬁciency with
a creatinine clearance of 30 ml/min and a urea of 120 mg/dl. She
was set on sirolimus/MMF; in the transition phase to that
regimen she had another, steroid-responsive ﬂare of her gut
GvHD. Eighteen months post-transplant, the girl’s GvHD is
under good control with sirolimus and low dose steroids. Renal
function tests are within normal limits. Conclusion: In HSCT
recipients with severe calcineurin-inhibitor neurotoxicity or im-
paired renal function, the use of sirolimus/MMF should be
considered when continuation of immunosuppressive therapy is
mandatory for control of GvHD.
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T CELLS OF RECIPIENT ORIGIN MEDIATE THE DEVELOPMENT OF
MURINE SYNGENEIC GRAFT-VERSUS-HOST DISEASE
Brandon, J.A.1, Jennings, C.D.2, Caywood, B.E.3, Perez, J.1,
Kaplan, A.M.1, Bryson, J.S.1,3 1. Department of Microbiology, Immu-
nology, and Molecular Genetics; 2. Department of Pathology; 3. Depart-
ment of Internal Medicine, Division of Hematology, Oncology and Blood
and Marrow Transplantation, University of Kentucky, Lexington, KY.
Syngeneic graft-versus-host disease (SGVHD), characterized
by a TH1 cytokine response, and intestinal inﬂammation devel-
ops following lethal irradiation, reconstitution with syngeneic
bone marrow, and treatment for 21 days with cyclosporine A
(CsA). It has generally been assumed that the T cell responses
associated with SGVHD resulted from the reconstitution of
irradiated recipients with donor bone marrow. However, to
determine the origin of the effector cells that mediate SGVHD,
syngeneic bone marrow from normal immunocompetent mice
or immunodeﬁcient mice were transferred into lethally irradi-
ated recipients. Following CsA treatment, mice within both
groups developed inﬂammation characteristic of SGVHD in the
colon and liver. Furthermore, increases in the expression of TH1
cytokines, levels of colonic CD4 T cells and expression of
activated peripheral CD4 T cells were comparable regardless
of whether CsA-treated animals received T cell sufﬁcient (nor-
mal) or T cell deﬁcient (SCID) bone marrow. These results
demonstrate that in the absence of donor T cells, recipient T
cells can expand and mediate the induction of CsA-induced
SGVHD.
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FATAL TUMOR LYSIS SYNDROME ASSOCIATED WITH INDUCTION OF
GRAFT-VS-HOST DISEASE IN A RELAPSED PATIENT WITH NASAL NK
CELL LYMPHOMA AFTER TANDEM AUTOLOGOUS–ALLOGENEIC STEM
CELL TRANSPLANTATION
Uryu, H.1, Koseki, M.1, Mori, Y.2, Niiya, D.3, Takeuchi, M.1,
Matsue, K.1 1. Kameda General Hospital, Internal Medicine, Depart-
ment of Hematology-Oncology, Kamogawa, Chiba Pref, Japan; 2. Ky-
ushu University, Fukuoka-City, Japan; 3. Okayama University,
Okayama-City, Japan.
The effective therapy for nasal natural-killer (NK) cell lym-
phoma is not established, and there is no report that the graft-
versus-lymphoma effect (GVLE) against the nasal NK cell lym-
phoma was deﬁnitively conﬁrmed. We report a patient with nasal
NK cell lymphoma who relapsed after allogeneic transplant and
developed fatal tumor lysis reaction during the attempt of inducing
graft-versus-host disease (GVHD). The patient was 53-year-old
woman suffering from a rapidly progressing nasal NK cell lym-
phoma metastasis to the skin, adrenal grand and abdominal lymph
nodes. She received three courses of combination chemotherapy
followed by high-dose therapy with a rescue of autologous haema-
topoietic stem cell transplant (HSCT). Following attainment of
partial remission, she underwent allogeneic HSCT from an HLA-
matched sibling prepared with reduced-intensity regimen and at-
tained complete remission. In the subsequent course, she had no
acute GVHD, but had extensive chronic GVHD mainly on skin,
requiring some immunosuppressions. Seven months after alloge-
neic HSCT, she developed fever and pancytopenia. A general
search revealed bone marrow relapse without any other lesion.
Immunosuppressions were tapered with expecting GVLE. Two
weeks after the withdrawal, she suddenly developed tachypnea.
Emergent laboratory data revealed signiﬁcant hyperkalemia, hy-
peruricemia, metabolic acidosis. We also found the marked de-
crease of tumor cells in a bone marrow aspiration specimen. After
the tumor lysis reaction, the patient developed severe renal and
hepatic dysfunction, causing her death despite intensive care. This





FACTORS PREDICT HEMATOPOIETIC RECOVERY IN PATIENTS WITH
FANCONI ANEMIA (FA) AFTER ALTERNATE DONOR (AD) HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT)
Al-Sweedan, S.A., Wagner, J.E., Tan, Y., DeFor, T.E.,
MacMillan, M.L. University of Minnesota, Minneapolis, MN.
As engraftment has been a signiﬁcant barrier to successful AD
HSCT (deﬁned as bone marrow [BM] or umbilical cord blood
[UCB] from a donor other than an HLA matched sibling), we
attempted to identify risk factors predictive of hematopoietic
recovery in this setting. Therefore, we evaluated engraftment in
83 FA patients aged 0.8–48.5 years (median 11.8) who under-
went T cell depleted BMT [(TCD, n  31), no TCD BMT (n 
37) or UCBT (n  15)] at the University of Minnesota from
1990 to 2004. 55% had aplastic anemia and 34% had myelodys-
plastic syndrome/acute myeloid leukemia at time of HSCT;
34% were CMV seropositive; 60% had HLA matched donors.
All received 40 mg/kg cyclophosphamide and 450 or 600 cGy
total body irradiation with 65% also treated with ﬂudarabine
(FLU) 140 mg/m2. BM Grafts contained 0.82–9.32  106CD34
cells/kg and 0.66–2.57  103 CD3 cells/kg and UCB grafts
contained 0.01– 0.91  106CD34 cells/kg and 0.03–0.24  103
CD3 cells/Kg. In univariate analysis, factors associated with
signiﬁcantly improved incidence of neutrophil recovery(	500/
uL) were no TCD-BM (94%) and TCD-BM in presence of
FLU (91%) compared to 83% and 68% in recipients of UCB
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